INTRODUCTION OF THE MEDICARE PATIENT ACCESS TO TECHNOLOGY ACT OF 1999 --
HON. JIM RAMSTAD (Extensions of Remarks - June 07, 1999)
[Page: E1154]
---
HON. JIM RAMSTAD
OF MINNESOTA
IN THE HOUSE OF REPRESENTATIVES
MONDAY, JUNE 7, 1999
- Mr. RAMSTAD. Mr. Speaker, new advances in medical technology are improving
the lives of millions of Americans every day:
- New implantable devices are restoring and repairing ailing organs.
- New diagnostics are permitting rapid detection of life-threatening
diseases and allowing physicians to peer inside the human body without
surgery.
- Miniature surgical devices are allowing patients to recover more quickly
and new technologies are empowering patients to monitor and test their
conditions from home and reduce or eliminate pain.
- Yet many of these life-saving and life-enhancing technologies remain
unavailable to the people who need them most, America's nearly 40 million
Medicare beneficiaries. This is because of the complex, interwoven systems
that Medicare uses to evaluate, approve and pay for new medical
technologies.
- That's why I am introducing ``The Medicare Patient Access to Technology
Act'' to make targeted adjustments in the technical methods and systems that
Medicare uses to adopt and pay for new medical products. By correcting and
coordinating the payment levels and identification codes, the bill will
improve access to needed therapies for millions of Medicare patients, both
today and in the future.
- As you know, Mr. Speaker, the Food and Drug Administration (FDA) reviews
medical technologies to ensure that they are ``safe and effective.'' After
passing through FDA, such technologies must also be deemed ``reasonable and
necessary'' by HCFA for them to be integrated into the portfolio of services
that Medicare makes available to its beneficiaries.
- After being approved for coverage, technologies must receive a ``procedure
code,'' a four or five digit identifying code that health care providers use
in submitting claims to payers.
- Finally, Medicare must set a payment level for each technology and
treatment through another reimbursement system designed for reimbursing
hospitals, physicians, skilled nursing facilities and other care
providers.
- Unfortunately, a problem at any of these stages can seriously delay a
product from reaching Medicare patients.
- For example, Mr. Speaker:
- Exogen, Inc., a small company that developed an ultrasound device for
healing bone fractures, has encountered 4 years of delays in getting Medicare
coverage. Oddly enough, the product is currently be reimbursed by more than
800 private insurers and health plans, but not by Medicare.
- The Cordis Corporation, a division of Johnson & Johnson, encountered
significant problems in obtaining appropriate Medicare coding and payment for
coronary stents, which are stainless steel tubes used to treat narrowing of
the coronary arteries. The company faced challenges in obtaining a unique code
for the stent procedure from HCFA, and once the new code was assigned,
Medicare took several more years to place the device in the appropriate
payment category. Sadly, the reason for the delay was Medicare's database was
only a partial data set and HCFA's precedent did not allow it to use sample
data in determining the hospital costs of providing the stent.
- A manufacturer of a cochlear ear implant halted active marketing of one
model and stopped research on another because of inadequate Medicare
reimbursements. According to an article that appeared in The New England
Journal of Medicine at the time, payment for the device remained well below
its average cost, causing hospitals to ``ration the availability of the device
to Medicare patients because of the financial losses involved. Eventually, so
few patients received the implant that the manufacturer discontinued its
production.'' (Nancy M. Kane, D.B.A., and Paul D. Manoukian, M.D., M.P.H.,
``The Effect of the Medicare Prospective Payment System on the Adoption of New
Technology,'' The New England Journal of Medicine, November 16, 1989, pp.
1378.1382.)
- The most distressing problem in all of these cases, as in many others just
like them, is that Medicare patients are being denied access to beneficial
therapies.
- I am pleased that HCFA is attempting to address the problems associated
with its process for making national coverage decisions for new technologies.
However, unless the shortcomings in the coding and payment systems are
corrected, HCFA will not fully achieve its ultimate goal of improving
Medicare's health care delivery system.
- Several distinct issues need to be addressed:
- Medicare's system for creating and assigning procedure codes to medical
technologies is cumbersome and slow.
- Medicare's methods of updating Medicare payment levels and payment groups
to accommodate changes in medical technology increase the risk that Medicare
will lag behind new advances in medical technology.
- Medicare's refusal to use data that are developed outside of the Medicare
program blinds the program to useful insights about the costs, charges and
outcomes of medical technologies.
- To address these issues, ``The Patient Access to Medical Technology Act of
1999'' would:
- 1. Adjust Medicare payment levels and payment categories at least annually
to reflect changes in medical practice and technology.
- 2. Use valid external sources of information to update payment categories
if Medicare's data are limited or not yet available. More specifically, the
bill directs HCFA to use a valid, statistically representative sample and also
to draw on external sources of data when its own dataset is inadequate. It
directs HCFA to consider statistically representative data from such sources
as private insurers, manufacturers, suppliers and other non-Medicare
entities.
- 3. Update national procedure codes (HCPCs Level II) more frequently to
reduce delays and timelags. Without an accurate identifying code, technologies
and procedures cannot be reimbursed appropriately by Medicare. It can take
HCFA up to 18 months to approve a new code because of the way the agency
structures its calendar for making such changes. This bill would make the
process more efficient by eliminating the single annual deadline for
applications and permitting such
[Page: E1155]
requests to be accepted on a rolling,
quarterly basis.
- 4. Continue to use local procedure codes to ensure availability of the
most recent advances in medical technology. Most coverage decisions are made
at the local level by local contractors, which use the ``HCPCS Level III
Codes'' to describe new technologies that have not yet been incorporated into
the national coding process. HCFA has proposed eliminating these useful codes,
but this bill would require HCFA to maintain this effective local
system.
- 5. Establish an advisory committee on Medicare coding and payment to
ensure that HCFA's coding and payment systems are open, prompt and functioning
properly. This panel would complement HCFA's newly formed Medicare Coverage
Advisory Committee.
- Mr. Speaker, this bill will correct a number of complex but significant
problems that currently plague HCFA's coverage, coding and payment systems.
Most importantly, it will help ensure that Medicare beneficiaries have timely
access to life-enhancing and life-saving medical advances.
- Mr. Speaker, I urge my colleagues to support this important legislation.
END